

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

HIGHLY SELECTIVE PDE4B INHIBITOR (SYH2059 POWDER FOR INHALATION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the highly selective PDE4B inhibitor (SYH2059 powder for inhalation) (the “**Product**”), a new Class 1 chemical drug developed by the Group, has obtained approval from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China. The Product also obtained approval from the U.S. Food and Drug Administration (FDA) in March 2026 to conduct clinical trials in the U.S.

The Product is a novel, highly active and highly selective phosphodiesterase 4B (PDE4B) inhibitor developed by the Group with complete independent intellectual property rights. The approved dosage form for this clinical trial is powder for inhalation. Preclinical studies demonstrated that the Product could significantly increase pulmonary drug concentrations and reduce systemic exposure, thereby reducing gastrointestinal side effects. Its efficacy in animal models of human disease was distinctly better than the existing drugs, with good pharmacokinetic characteristics and a broad safety margin.

The indication for this approved clinical trial is interstitial lung disease. Currently, there are few drugs on the market available for the treatment of these diseases, and patients have limited benefit from these treatments. The Product has the potential to become an effective drug for the treatment of this disease, providing a promising clinical development value. The approval of the Product for clinical trials represents a key achievement of the Group’s high-end innovative inhalation technology platform, and lays a solid foundation for the development of subsequent innovative inhalation formulations within the Group’s pipeline.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 16 March 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.